Budget Impact Analysis of Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction (HFrEF) in Indonesia
Based on PARADIGM-HF Clinical Trials, LCZ696, a dual-acting sodiumsupramolecular complex currently known as sacubitril/valsartan, wassuperior to enalapril in reducing the risks of death and hospitalization forheart failure (HF) in patients with heart failure and reduced ejection fraction(HFrEF). This analysis aimed to estimate the budget impact ofsacubitril/valsartan in the treatment of HFrEF in Indonesia setting. A … Read more